Your browser is no longer supported. Please, upgrade your browser.
Settings
VTRS [NASD]
Viatris Inc.
IndexS&P 500 P/E- EPS (ttm)-1.91 Insider Own0.10% Shs Outstand1.21B Perf Week-4.78%
Market Cap15.79B Forward P/E3.42 EPS next Y3.72 Insider Trans0.00% Shs Float1.21B Perf Month-2.67%
Income-1921.10M PEG- EPS next Q0.92 Inst Own75.00% Short Float2.56% Perf Quarter-11.27%
Sales17.17B P/S0.92 EPS this Y-7.80% Inst Trans-1.75% Short Ratio3.68 Perf Half Y-16.34%
Book/sh17.48 P/B0.73 EPS next Y0.38% ROA-3.30% Target Price19.17 Perf Year-25.31%
Cash/sh0.68 P/C18.70 EPS next 5Y-0.35% ROE-8.90% 52W Range12.90 - 18.86 Perf YTD-31.96%
Dividend0.44 P/FCF7.81 EPS past 5Y-21.60% ROI-0.40% 52W High-32.40% Beta1.42
Dividend %3.45% Quick Ratio0.70 Sales past 5Y4.80% Gross Margin34.40% 52W Low-1.16% ATR0.35
Employees45000 Current Ratio1.10 Sales Q/Q52.60% Oper. Margin-4.90% RSI (14)32.07 Volatility2.13% 2.49%
OptionableYes Debt/Eq1.11 EPS Q/Q-28.40% Profit Margin-11.20% Rel Volume1.35 Prev Close13.05
ShortableYes LT Debt/Eq0.94 EarningsNov 08 BMO Payout- Avg Volume8.40M Price12.75
Recom2.40 SMA20-7.35% SMA50-6.52% SMA200-11.04% Volume11,373,634 Change-2.30%
Jun-15-21Initiated Citigroup Neutral $16
Apr-07-21Resumed RBC Capital Mkts Outperform $24
Mar-08-21Downgrade Goldman Buy → Neutral $20 → $15
Mar-02-21Downgrade JP Morgan Overweight → Neutral $21 → $18
Feb-26-21Downgrade Wolfe Research Outperform → Peer Perform $17
Jan-05-21Initiated Argus Hold
Dec-14-20Initiated Bernstein Mkt Perform $21
Nov-25-21 05:55AM  
Nov-24-21 09:31AM  
Nov-22-21 06:55AM  
06:00AM  
Nov-21-21 06:55AM  
Nov-18-21 06:59AM  
Nov-17-21 02:27PM  
05:55AM  
Nov-16-21 06:59AM  
Nov-13-21 11:00AM  
Nov-12-21 04:11PM  
05:51AM  
Nov-11-21 11:38AM  
06:59AM  
Nov-10-21 10:53AM  
Nov-08-21 02:30PM  
02:16PM  
10:01AM  
08:35AM  
06:59AM  
Nov-07-21 06:04AM  
Nov-05-21 10:09AM  
Nov-04-21 09:39AM  
Nov-02-21 05:50PM  
07:43AM  
Nov-01-21 03:02PM  
Oct-27-21 10:14AM  
05:52AM  
Oct-25-21 10:39AM  
Oct-23-21 06:15AM  
Oct-22-21 10:19AM  
05:52AM  
Oct-21-21 08:30AM  
Oct-20-21 01:23PM  
11:37AM  
07:05AM  
07:00AM  
Oct-16-21 06:04AM  
Oct-15-21 09:29AM  
06:45AM  
Oct-14-21 05:51AM  
Oct-13-21 08:00AM  
Oct-11-21 07:30AM  
Oct-07-21 08:15AM  
Oct-06-21 05:51AM  
Oct-04-21 11:41AM  
Oct-01-21 08:45PM  
Sep-29-21 02:26PM  
05:51AM  
Sep-28-21 05:47AM  
Sep-27-21 06:00AM  
Sep-17-21 05:32PM  
05:19PM  
12:35PM  
06:06AM  
Sep-13-21 05:55AM  
Sep-08-21 11:30AM  
Sep-05-21 05:55AM  
Sep-04-21 06:49AM  
06:06AM  
Sep-02-21 09:30AM  
Aug-30-21 08:00AM  
08:00AM  
Aug-27-21 06:12AM  
Aug-24-21 09:32AM  
08:23AM  
05:00AM  
Aug-21-21 11:36AM  
Aug-16-21 11:01AM  
Aug-09-21 03:30PM  
10:33AM  
06:59AM  
Aug-06-21 08:26PM  
06:23PM  
Aug-05-21 05:50PM  
Aug-04-21 09:44AM  
08:21AM  
Aug-03-21 12:38PM  
Jul-30-21 05:50PM  
Jul-29-21 08:12AM  
Jul-28-21 11:29PM  
Jul-27-21 07:30AM  
Jul-23-21 05:52AM  
Jul-17-21 06:08AM  
Jul-16-21 08:42AM  
12:02AM  
Jul-08-21 01:59PM  
Jul-06-21 11:49AM  
05:55AM  
Jun-30-21 05:51AM  
Jun-29-21 06:49AM  
Jun-24-21 09:57AM  
Jun-23-21 08:23PM  
Jun-16-21 04:42PM  
05:51AM  
Jun-12-21 12:14PM  
Jun-11-21 05:55AM  
Jun-10-21 01:22PM  
05:52AM  
Jun-08-21 12:29PM  
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COURY ROBERT JExecutive ChairmanJun 24Option Exercise0.00250,00001,633,587Jun 25 07:00 PM
CORNWELL W DONDirectorMay 21Buy15.455007,7255,000May 21 06:00 PM
CORNWELL W DONDirectorMay 19Buy15.791,50023,6904,500May 21 06:00 PM
CORNWELL W DONDirectorMar 03Buy13.843,00041,5153,000Mar 04 06:35 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.009,440025,049Mar 04 06:36 PM
MARK RICHARD ADirectorMar 02Option Exercise0.009,440018,668Mar 04 06:36 PM
Malik RajivPresidentMar 02Option Exercise0.00174,0170174,017Mar 04 06:36 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.009,440015,705Mar 04 06:35 PM
KORMAN HARRYDirectorMar 02Option Exercise0.009,440036,141Mar 04 06:35 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.009,440048,571Mar 04 06:35 PM
PARRISH MARK WDirectorMar 02Option Exercise0.009,440067,753Mar 04 06:35 PM
Mauro AnthonySee RemarksMar 02Option Exercise0.0076,5650173,164Mar 04 06:35 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,67501,823Mar 04 06:35 PM
Campbell PaulSee RemarksMar 02Option Exercise0.0022,874046,133Mar 04 06:35 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.009,440060,703Mar 04 06:35 PM
GOETTLER MICHAELChief Executive OfficerFeb 22Option Exercise0.003,49907,603Feb 24 06:01 PM
KILTS JAMES MDirectorDec 16Buy17.6627,736489,69364,905Dec 18 06:00 PM